Abstract
BackgroundOral glucocorticoids (GC) are the mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) but chronic exposure to GC is associated with serious comorbidities. Mepolizumab (MEPO) demonstrated to be an...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
